{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T08:09:53Z","timestamp":1788768593225,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016359","name":"Wuhan University Zhongnan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102834","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:19:18Z","timestamp":1782789558000},"page":"102834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fractionated high-dose vitamin c sustains higher plasma trough concentrations in advanced solid tumors: a phase I clinical study"],"prefix":"10.1016","volume":"71","author":[{"given":"Qing","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1465-6102","authenticated-orcid":false,"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.tranon.2026.102834_bib0001","doi-asserted-by":"crossref","first-page":"13604","DOI":"10.1073\/pnas.0506390102","article-title":"Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues","volume":"102","author":"Chen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.tranon.2026.102834_bib0002","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s12094-024-03553-x","article-title":"High-dose vitamin C as a metabolic treatment of cancer: a new dimension in the era of adjuvant and intensive therapy","volume":"27","author":"Wang","year":"2025","journal-title":"Clin. Transl. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.102834_bib0003","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41568-019-0135-7","article-title":"Targeting cancer vulnerabilities with high-dose vitamin C","volume":"19","author":"Ngo","year":"2019","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.102834_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-017-0044-8","article-title":"Vitamin C preferentially kills cancer stem cells in hepatocellular carcinoma via SVCT-2","volume":"2","author":"Lv","year":"2018","journal-title":"NPJ Precis. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.102834_bib0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1078-0432.CCR-09-1713","article-title":"Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer","volume":"16","author":"Du","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.tranon.2026.102834_bib0006","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/138920101609150715135921","article-title":"Treatment of pancreatic cancer with pharmacological ascorbate","volume":"16","author":"Cieslak","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"6266","key":"10.1016\/j.tranon.2026.102834_bib0007","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1126\/science.aaa5004","article-title":"Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH","volume":"350","author":"Yun","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tranon.2026.102834_bib0008","first-page":"694","article-title":"Redox active metals and H2O2 mediate the selective efficacy of pharmacological ascorbate in sarcoma","volume":"14","author":"Schoenfeld","year":"2017","journal-title":"Redox. Biol."},{"issue":"10","key":"10.1016\/j.tranon.2026.102834_bib0009","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1073\/pnas.73.10.3685","article-title":"Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer","volume":"73","author":"Cameron","year":"1976","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.tranon.2026.102834_bib0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0009-2797(74)90019-2","article-title":"The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer","volume":"9","author":"Cameron","year":"1974","journal-title":"Chem. Biol. Interact."},{"issue":"13","key":"10.1016\/j.tranon.2026.102834_bib0011","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJM197909273011303","article-title":"Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial","volume":"301","author":"Creagan","year":"1979","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.102834_bib0012","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM198501173120301","article-title":"High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison","volume":"312","author":"Moertel","year":"1985","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.tranon.2026.102834_bib0013","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/annonc\/mdn377","article-title":"Phase I clinical trial of i.v. ascorbic acid in advanced malignancy","volume":"19","author":"Hoffer","year":"2008","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.102834_bib0014","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-013-2179-9","article-title":"Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer","volume":"72","author":"Stephenson","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.tranon.2026.102834_bib0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-013-2070-8","article-title":"Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial","volume":"71","author":"Welsh","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102834_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103375","article-title":"A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer","volume":"77","author":"Bodeker","year":"2024","journal-title":"Redox. Biol."},{"issue":"19","key":"10.1016\/j.tranon.2026.102834_bib0017","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-22-0655","article-title":"A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX \u00b1 Bevacizumab versus FOLFOX \u00b1 bevacizumab in unresectable untreated metastatic colorectal cancer (VITALITY Study)","volume":"28","author":"Wang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102834_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103726","article-title":"High-dose vitamin C as a targeted treatment for KRAS-driven cancers?","volume":"85","author":"Mack","year":"2025","journal-title":"Redox. Biol."},{"issue":"8","key":"10.1016\/j.tranon.2026.102834_bib0019","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1158\/2767-9764.CRC-24-0225","article-title":"High-dose intravenous vitamin C combined with Docetaxel in men with metastatic castration-resistant prostate cancer: a randomized placebo-controlled phase II trial","volume":"4","author":"Paller","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"2 suppl","key":"10.1016\/j.tranon.2026.102834_bib0020","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/j.ijrobp.2023.06.1287","article-title":"Efficacy and safety of high-dose vitamin C combined with total neoadjuvant chemoradiotherapy in locally advanced rectal cancer (HCCSC R02 Study)","volume":"117","author":"Dai","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.tranon.2026.102834_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.radmp.2024.05.002","article-title":"Treatment of severe radiation proctitis with high dosage of vitamin C in combination with cyclooxygenase-2 inhibitor","volume":"5","author":"Wu","year":"2024","journal-title":"Radiat. Med. Prot."},{"issue":"10","key":"10.1016\/j.tranon.2026.102834_bib0022","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3390\/nu11102412","article-title":"The pharmacokinetics of vitamin C","volume":"11","author":"Lykkesfeldt","year":"2019","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.tranon.2026.102834_bib0023","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C pharmacokinetics: implications for oral and intravenous use","volume":"140","author":"Padayatty","year":"2004","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.tranon.2026.102834_bib0024","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1073\/pnas.93.8.3704","article-title":"Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance","volume":"93","author":"Levine","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.tranon.2026.102834_bib0025","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s40262-022-01142-1","article-title":"Pharmacokinetic evaluation of intravenous vitamin C: a classic Pharmacokinetic study","volume":"61","author":"Chen","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.tranon.2026.102834_bib0026","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0003-2697(89)90243-1","article-title":"Ascorbic acid analysis using high-performance liquid chromatography with coulometric electrochemical detection","volume":"181","author":"Washko","year":"1989","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.tranon.2026.102834_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0003-2697(92)90131-P","article-title":"Ascorbic acid and dehydroascorbic acid analyses in biological samples","volume":"204","author":"Washko","year":"1992","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.tranon.2026.102834_bib0028","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.redox.2016.10.010","article-title":"Tumor cells have decreased ability to metabolize H2O2: implications for pharmacological ascorbate in cancer therapy","volume":"10","author":"Doskey","year":"2016","journal-title":"Redox. Biol."},{"key":"10.1016\/j.tranon.2026.102834_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103288","article-title":"Redox-active vitamin C suppresses human osteosarcoma growth by triggering intracellular ROS-iron-calcium signaling crosstalk and mitochondrial dysfunction","volume":"75","author":"Vaishampayan","year":"2024","journal-title":"Redox. Biol."},{"key":"10.1016\/j.tranon.2026.102834_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101980","article-title":"Peroxiredoxin 2 oxidation reveals hydrogen peroxide generation within erythrocytes during high-dose vitamin C administration","volume":"43","author":"Pearson","year":"2021","journal-title":"Redox. Biol."},{"issue":"7","key":"10.1016\/j.tranon.2026.102834_bib0031","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1097\/CCM.0000000000004396","article-title":"Harm of IV high-dose vitamin C therapy in adult patients: a scoping review","volume":"48","author":"Yanase","year":"2020","journal-title":"Crit. Care Med."}],"updated-by":[{"DOI":"10.1016\/j.tranon.2026.103009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000}},{"DOI":"10.1016\/j.tranon.2026.103009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000}}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326001713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:25:20Z","timestamp":1787225120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S1936523326001713"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102834","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fractionated high-dose vitamin c sustains higher plasma trough concentrations in advanced solid tumors: a phase I clinical study","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102834"}}